€3.31
-0.04 (-1.19%)
EUR · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where OSE.PA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
8 interventional · 2 with posted results
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or LymphomasNCT05751798Part A: Occurrence of dose limiting toxicity (DLT). Part B: Safety and tolerability of the combination OSE-279/OSE2101. Part C: Overall response rate (ORR) of the combination OSE-279/OSE2101Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: Part A: OSE-279 100mg, Part A: OSE-279 300mg, Part A: OSE-279 600mg, Part B: OSE-279 600 mg and OSE2101, Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positive, Part C: OSE-279 600 mg - HLA-A2 positif, Part C: OSE-279 600 mg - HLA-A2 negative | Solid Advanced Tumor, Lymphoma, NSCLC (Non-small Cell Lung Cancer) | 41 | Dec 2029 | ≤ 1,229 d | 2026-06-04 |
| Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint InhibitorNCT06472245OS defined as time from randomization to deathRandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: OSE2101, Docetaxel · Device: NGS HLAA2 assay | Patients With Non-Small Cell Lung Cancer | 363 | 2027-12-15 | in 482 d | 2026-07-23 |
| Study of OSE-127 vs Placebo in Patients With Moderate to Severe Active Ulcerative ColitisNCT04882007results2026-06-23Change From Baseline in Modified Mayo Score (MMS) at Week 10Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: OSE-127, Placebo | Ulcerative Colitis | 136 | 2024-04-30actual | — | 2026-06-23 |
| A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid TumoursNCT03990233Step 1 (dose escalation Parts A and B): Number of patients with Dose-Limiting Toxicities (DLTs) during the first treatment cycleRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: BI 765063, BI 754091 | Solid Tumor, Adult | 100 | 2023-04-17actual | — | 2025-06-26 |
| To Evaluate the Safety, and Immunogenicity of Vaccine Candidate Against COVID-19, in Healthy AdultsNCT04885361The incidence of solicited local reactogenicity signs and symptomsRandomized · Open-label · Treatment | Phase 1 | Unknown status | Biological: CoVepiT (OSE13E) | Coronavirus Disease (COVID-19) | 48 | 2021-09-30 | — | 2021-06-09 |
| OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor FailureNCT02654587results2024-02-02Overall Survival (OS)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: due to COVID-19 | Biological: OSE2101 · Drug: Docetaxel, Pemetrexed | Non Small Cell Lung Cancer | 219 | 2021-01-15actual | — | 2024-02-02 |
| Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of OSE-127 in Healthy SubjectsNCT03980080Part 1 (SAD) & Part 2 (MAD) : Number of Participants With Treatment Emergent Adverse Events (TEAEs)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: OSE-127, Placebo, OSE-127 | Healthy Subjects | 63 | 2019-11-04actual | — | 2019-12-12 |
| Safety, Tolerability, PK, PD, and Immunogenicity of Single and Multiple Ascending Intravenous Doses of FR104NCT02800811Type, incidence, severity, timing, seriousness and relatedness of treatment emergent adverse events, and abnormalities in laboratory parameters in healthy volunteers of FR104 compared to placebo after single (SAD) and two IV doses (MAD).Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: FR104, Placebo | Rheumatoid Arthritis, Complication of Transplant | 64 | Jun 2016actual | — | 2016-07-21 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19